Comparative Pharmacology
Head-to-head clinical analysis: DILAUDID HP versus SUBSYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILAUDID HP versus SUBSYS.
DILAUDID-HP vs SUBSYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.
SUBSYS (fentanyl) is a mu-opioid receptor agonist that produces analgesia by mimicking endogenous opioids, increasing potassium efflux and reducing calcium influx, thereby inhibiting neuronal transmission of pain signals.
Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.
SUBSYS (fentanyl buccal soluble film) is indicated for breakthrough pain in opioid-tolerant patients. Initial dose: 100 mcg (one 100 mcg film) placed on the inner cheek, allowed to dissolve over 15-25 minutes; may repeat once after 30 minutes if pain not relieved. Titrate to effective dose (200, 400, 600, 800, 1200, 1600 mcg). Maximum: 4 doses per day. No more than 2 doses per breakthrough pain episode. Wait at least 2 hours before treating next episode.
None Documented
None Documented
Terminal elimination half-life: 2.3–4 hours. In clinical context, consistent with dosing interval of 4–6 hours for immediate-release formulations; prolonged in hepatic or renal impairment.
Terminal half-life 2–4 hours (single dose); prolonged to 7–15 hours in hepatic/renal impairment; clinical context: necessitates q4–6h dosing for chronic pain.
Renal: predominantly as hydromorphone-3-glucuronide (H3G), unchanged hydromorphone (<6%), and other metabolites. Biliary/fecal: minimal.
Primarily renal (~75% as metabolites, <10% unchanged); biliary/fecal excretion of conjugates; ~9% in feces.
Category C
Category C
Opioid Analgesic
Opioid Analgesic